Breast cancer: The value of preoperative chemotherapy

American Journal of Cancer

Volumn 1, Issue 2, 2002, Pages 121-126

  Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOPPLER FLOWMETER; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MEDICAL EXAMINATION; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENTINEL LYMPH NODE; TREATMENT OUTCOME;

EID: 0037593424     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201020-00005     Document Type: Review

References (39)

1. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 2412-7
2. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988: 62: 2507-16
3. Buzdar AU, Hortobagyi GN, Asmar L, et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast ca ncer. Semin Oncol 1997; 24: S17-34
4. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999; 230: 72-8
5. Broadwater JR, Edwards MJ, Kuglen C, et al. Mastectomy following preoperative chemotherapy. Ann Surg 1991; 213: 126-9
6. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9
7. Meric F, Mirza NQ, Buzdar AU, et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T2N0M0 breast cancer. Ann Surg Oncol 2000; 7: 435-40
8. Singletary SE. Management of locally advanced breast cancer [editorial overview]. The Commission on Cancer of the American College of Surgeons. Hagerstown (MD): Lippicott, Williams and Wilken, 1998: 1-19
9. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7
10. Koscielny S, Tubiana M, Le MG, et al. Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer 1984; 49: 709-15
11. Vlastos G, Mirza NQ, Lenert JT, et al. The feasibility of minimally invasive surgery in stage IIA, IIB, and IIIA breast cancer patients after tumor downstaging with induction chemotherapy. Cancer 2000; 88: 1417-24
12. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast conservation surgery after induction chemotherapy for locally advanced carcinoma. Cancer 1992; 69: 2849-52
13. American Joint Committee on Cancer. Manual for staging of cancer. 3rd ed. Philadelphia (PA): Lippincott, 1988: 145-50
14. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-45
15. Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119-29
16. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumor considered too large for breast conserving surgery: preliminary results of a randomized trial: S6. Eur J Cancer 1994; 30A: 645-52
17. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222: 612-8
18. Powles TJ, Hickesh TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547-52
19. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85
20. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100
21. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998: 9: 1179-84
22. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52
23. Peoples G, Heaton K, Booser D, et al. Breast conservation therapy for large primary and locally advanced breast cancers after induction chemotherapy [abstract]. Society of Surgical Oncology 51st Annual Cancer Symposium; 1998 Mar; San Diego
24. Singletary SE, Kuerer HM. Preoperative (neoadjuvant) systemic therapy for operable breast cancer. In: Perry MC, editor. American Society Clinical Oncology educational book. Baltimore (MD): Lippincott Williams & Wilkins, 2001: 524-8
25. Lenert JT, Vlastos G, Mirza NQ, et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 1999; 6: 762-7
26. Singletary SE. Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what and why? J Am Coll Surg 2001; 192: 220-30
27. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate following neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18: 3480-6
28. Haid A, Tausch C, Lang A. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001; 92: 1080-4
29. Mamounas E, Brown A, Smith R, et al. Sentinel node biopsy (SNB) following neoadjuvant chemotherapy in breast cancer: results from NSABP B-27 [abstract]. Society of Surgical Oncology 54th Annual Cancer Symposium; 2001 Mar 15-18; Washington. DC
30. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18: 1558-69
31. Soderstrom CE, Harms SE, Farrell Jr RS, et al. Detection with MR imaging of residual tumor in the breast soon after surgery. Am J Roentgenol 1997; 68: 485-8
32. Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996; 78: 91-100
33. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17: 110-9
34. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95
35. Huber S, Medi M, Helbich T, et al. Locally advance breast carcinoma: computer assisted semiquantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy. J Ultrasound Med 2000; 19: 601-7
36. Mirza AN, Fornage BD, Sneige N, et al. Radiofrequency ablation of solid tumors. Cancer J 2001; 7: 95-102
37. Jeffrey SS, Birdwell RL, Ikeda DM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg 1999; 134: 1064-8
38. Izzo F, Thomas, R, et al. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 16 patients. Cancer 2001; 92: 2036-44
39. Singletary SE. Sequencing therapeutic interventions in early and advanced primary breast cancer. Semin Breast Dis 1999; 2: 145-56